According to a multi-center clinical trial led by researchers at the Stanford University School of Medicine, a new type of immunotherapy seems to be safe for patients with blood cancer called non-Hodgkin’s lymphoma.
The therapy combines experimental antibodies developed by researchers at Stanford University and commercially available anti-cancer antibodies to rituximab. It referred Hu5F9-G4 experimental protein antibody blockade of CD47 , of CD47 suppressed immune attack against cancer cells. The combination of two antibodies is used to treat people with two types of non-Hodgkin-lymfoom: diffuse large B- cell lymphoma and follicular lymphoma.
In 2010 toonden onderzoekers onder leiding van Irving Weissman, MD, directeur van het Stanford Stem Cell Biology and Regenerative Medicine Institute, aan dat bijna alle kankercellen bedekt zijn met een eiwit genaamd CD47, dat een "eet me niet op"-signaal kan spelen voor macrofagen.
Weissman and colleagues later developed an antibody called Hu5F9-G4 that blocks the CD47 protein and encourages macrophages to engulf cancer cells. Rituximab is an antibody that has been shown to amplify the positive ” eat me ” signal. The combination of rituximab and Hu5F-G4 has previously been shown to be effective against human cancer in animal models, but this is the first published result of clinical trials of the therapy in humans.
Van de 22 patiënten die aan het onderzoek deelnamen, hadden 11 patiënten significant minder klinische kanker, en 8 patiënten hadden alle tekenen van kanker geëlimineerd. De andere drie patiënten in het onderzoek reageerden niet op de behandeling en stierven als gevolg van ziekteprogressie. De onderzoekers constateerden dat de deelnemers slechts geringe bijwerkingen hadden.
Dr. Saul A. Rosenberg , a lymphoma professor , said that such a potential new immunotherapie is very exciting. This is the first time that an antibody that can activate macrophages to fight cancer is used, and it seems to be safe for use in humans.
https://medicalxpress.com/news/2018-10-anti-cd47-cancer-therapy-safe-small.html
